MOTS-C 40mg

MOTS-C is generally well-tolerated, with most reported side effects being mild and dose-dependent.  The most common issues include mild injection-site reactions (redness, irritation, or swelling), temporary fatigue, and occasional headaches. 

Other potential side effects include:

• Metabolic shifts: Temporary fluctuations in blood sugar, which may cause dizziness or lightheadedness, particularly in fasting states. 

• Gastrointestinal discomfort: Mild nausea or digestive upset, though this is less common than with other metabolic peptides. 

• Appetite changes: Users may experience decreased appetite or unintentional weight loss due to enhanced fat oxidation. 

• Cardiovascular effects: Some self-experimenters report increased heart rate or palpitations, though this is not universally reported. 

• Sleep disturbances: Insomnia has been noted in some anecdotal reports. 

Important Context: Long-term human safety data is limited as MOTS-C is not FDA-approved and remains a research peptide.  Severe side effects are rare, but users are advised to start with low doses, monitor blood sugar levels, and consult a healthcare professional, especially if they have pre-existing metabolic conditions or are taking medications like metformin. 

Common research-planning tiers include:

• Starting Tier: 5 mg administered twice weekly for 4 weeks to assess tolerance. 

• Standard Tier: 5 mg administered three times weekly for 4–6 weeks. 

• Higher Tier: 10 mg administered 2–3 times weekly for 6–8 weeks. 

Alternative protocols found in community guides include:

• 20-Day Cycle: 5 mg injected once every 5 days (4 total injections), followed by a 4-month rest. 

• Daily Titration: Starting at 200–500 mcg daily and gradually increasing to 1–2 mg daily over 8–12 weeks. 

• Conservative: 1 mg administered 5 days on, 2 days off for 8 weeks. 

Most users report cumulative metabolic effects rather than acute changes, with typical cycles lasting 8 to 12 weeks followed by a break period.  Side effects may include injection-site reactions, flushing, or mild fatigue. Consult a healthcare provider before use, as MOTS-c is prohibited by WADA.